ArticlePloS one2026
Choroidal metastasis: Impact of primary tumors and age on survival - a single center analysis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to determine whether patient's age and their primary tumor type act as independent predictors of their survival after a diagnosis of choroidal metastasis.
methodsThis retrospective single-center study (August 2013 - August 2025) included 70 patients with choroidal metastases. Clinical data and multimodal imaging were extracted from medical records. Tumor volume was calculated from ultrasound measurements. Patients were grouped according to primary tumor origin (lung, breast, or other primaries). Survival was compared between these three primary tumor groups and according to age. Group differences in continuous variables were assessed using ANOVA/Kruskal-Wallis testing, and survival distributions were analyzed with Kaplan-Meier curves. Patients were categorized into younger (<59.6 years) and older (≥59.6 years) groups for Kaplan-Meier survival analysis. Univariate and multivariate Cox regression models were performed to identify independent predictors of overall survival.
resultsMedian overall survival was 71.6 weeks. Statistically significantly longer survival was found in patients <59.6 years (median 88.3 weeks; estimated 3-year survival 33.2%) compared with those ≥59.6 years (median 41.9 weeks; 3-year survival 16.8%; p = 0.037. Primary tumor group analysis showed a median survival of 94.4 weeks for breast cancer (estimated 3-year survival 38.3%), 52.7 weeks for lung cancer (9,5%), and 40.6 weeks for other primaries (19.7%). However, this difference was not statistically significant (p = 0.269). In multivariate Cox regression analysis, age ≥ 59.6 years (HR 2.10; p = 0.016) and >1 extraocular metastases elsewhere in the body (HR 2.53; p = 0.029) were independent predictors of mortality.
conclusionSurvival in choroidal metastases is strongly driven by age and the number of extraocular metastatic sites at presentation. Our findings suggest that younger age and a lower metastatic burden are most reliable indicators for a more favorable prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.